Released February 04, 2021 | KOFU, JAPAN
en
The use of eye drops has increased as more workers stay at home due to COVID-19 precautions and perform more work online.
As a result, a number of pharmaceutical companies in South Korea have recently begun to expand their production lines for the treatment of ophthalmic diseases. Kukje Pharma has begun work on a plant expansion and is preparing for production in earnest. Also, DHP Korea plans to expand its production lines.
Huons has begun the construction of a second plant exclusively for eye drops in the Bio Valley of Jecheon City. The company plans to increase production volume by 60%, making it among the largest South Korean pharmaceutical companies that have facilities for producing eye drops. It is understood that it is planning to export its products overseas as well as provide them in South Korea.
Click here for a list of projects and see a map below.
As a result, a number of pharmaceutical companies in South Korea have recently begun to expand their production lines for the treatment of ophthalmic diseases. Kukje Pharma has begun work on a plant expansion and is preparing for production in earnest. Also, DHP Korea plans to expand its production lines.
Huons has begun the construction of a second plant exclusively for eye drops in the Bio Valley of Jecheon City. The company plans to increase production volume by 60%, making it among the largest South Korean pharmaceutical companies that have facilities for producing eye drops. It is understood that it is planning to export its products overseas as well as provide them in South Korea.
Click here for a list of projects and see a map below.
